ClinicalTrials.gg
CompletedNCT05419180Updated Jul 24, 2024

Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies

A Phase 4 interventional study of Stiripentol in Pharmacoresistant Focal Epilepsies, sponsored by Biocodex. Completed at 1 site in France. Per ClinicalTrials.gov, last updated 2024-07-24.

Sponsored by Biocodex · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Epilepsies, Partial with a site in France — 11 open to participants now, 12 under way, 2 of them phase 3. Epilepsies, Partial · France.

Enrollment
25th of 27
52 · median 157
Started
2022
with 3 others
Phase 4
4 of 40
none open now
Registered
34th of 40
by date

Among the 40 studies in Epilepsies, Partial with a site in France, this one is the 25th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2022, is one of 4 in phase 4, and was the 34th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

11 of the 40 studies in Epilepsies, Partial with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Epilepsies, Partial with a site in France, or all of them as a file.
02

Study summary

This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (Diacomit®) and Carbamazepine.

03

Conditions studied

  • Pharmacoresistant Focal Epilepsies

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Retrospective part of the research:

The medical records of CRéER patients with the following criteria will be included in the retrospective part of the research by an investigator:

  1. With pharmacoresistant epilepsy, i.e. a history of failure of two well-conducted and well-tolerated antiepileptic treatment regimens, either as monotherapy or as combination therapy,
  2. Receiving or having received a treatment combining stiripentol and carbamazepine for a period of at least 15 days,
  3. Having at least one evaluation data after the initiation of treatment with stiripentol and carbamazepine (a follow-up visit after the initiation of the study treatment),
  4. For which an information note indicating the possibility of opposing the processing of data has been provided.

    • Prospective part of the research:

Among the patients whose medical records are included in the retrospective part of the research, those who meet the following criteria will be able to participate in the prospective part of the research:

  1. Currently treated with stiripentol in combination with carbamazepine for at least 15 days and still being followed in the center,
  2. Weighing at least 5 kg (minimum weight in accordance with the blood volume taken),
  3. Having read, or whose parents have read, the information note and signed the consent form. For children, if their level of understanding allows it, their consent will also be sought,
  4. Having sufficient knowledge, or whose parents or legal guardians have sufficient knowledge, of the French language to read, understand and complete the research documents,
  5. Members or beneficiaries of a social security scheme. These patients, both children and adults, will be welcomed at the CIC.

Exclusion criteria

Exclusion Criteria:

  • Retrospective part of the research : Patients objecting to the collection of their data will not participate in the research.
  • Prospective part of the research :

Patients with the following criteria will not be able to participate in the prospective part of the research:

  1. Participating simultaneously in another interventional clinical trial or in a period of exclusion following a previous trial,
  2. Whose state of health does not allow him to give his consent,
  3. Under guardianship or curatorship,
  4. Under judicial protection or person deprived of liberty.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Other
    stiripentol

    Drug: Stiripentol

Interventions

  • Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients.

06

What researchers measure

Primary outcomes

  1. Age

    Age of onset, nature of the first seizure and description of the type of the first seizure.

    Time frame: through study completion, an average of 1 year

  2. Previous antiepileptic treatments received

    proportion of patients having received each antiepileptic treatment; for the treatments received, description of the reasons for stopping.

    Time frame: through study completion, an average of 1 year

  3. Surgery

    proportion of patients having undergone epilepsy surgery.

    Time frame: through study completion, an average of 1 year

  4. Adjustment of carbamazepine treatment over the time

    mean and median duration of treatment, mean and median daily dose received, dose change(s) during treatment...

    Time frame: through study completion, an average of 1 year

  5. Adjustment of stiripentol treatment over the time

    mean and median duration of treatment, mean and median daily dose received, dose change(s) during treatment...

    Time frame: through study completion, an average of 1 year

  6. Adjustment of concomitant treatments over the time

    continuation without change, change in dosage, discontinuation

    Time frame: through study completion, an average of 1 year

  7. monthly seizures over the time

    description of the average number of monthly seizures since the last visit (total and by type of seizure)

    Time frame: through study completion, an average of 1 year

  8. status epilepticus in the past

    proportion of patients who presented with status epilepticus

    Time frame: through study completion, an average of 1 year

  9. duration of the status epileticus over the time

    duration of status epilepticus

    Time frame: through study completion, an average of 1 year

  10. emergency room consultation and/or hospitalization over the time

    Proportion of patients requiring an emergency room consultation and/or hospitalized during the period preceding the visit.

    Time frame: through study completion, an average of 1 year

  11. emergency antiepileptic treatment over the time

    Proportion of patients taking emergency antiepileptic treatment in the period before each visit

    Time frame: through study completion, an average of 1 year

  12. frequency of the status epileticus over the time

    frequency of status epilepticus

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Retention rate of the combination

    The retention rate of the combination will correspond to the proportion of patients still receiving the combination (carbamazepine and stiripentol) at a given time.

    Time frame: through study completion, an average of 1 year

  2. Response to the combination

    The rate of patients responding to the combination will be defined by the percentage of patients in whom a 50% reduction in visible seizures will be observed since the initiation of the carbamazepine and stiripentol combination. Will be estimated: oThe percentage of responder patients at the post-initiation visit of the combination (first follow-up visit after initiation of stiripentol) oThe percentage of responder patients during treatment regardless of the duration of treatment after which the response is obtained. oThe cumulative incidence of responder patients.

    Time frame: through study completion, an average of 1 year

  3. Tolerance of the combination.

    Proportion of patients with Adverse Effects (AEs) related to the combination or to one of the treatments,

    Time frame: through study completion, an average of 1 year

  4. Frequency and nature of the adverse events over the time

    Frequency and nature of the adverse events over the time

    Time frame: through study completion, an average of 1 year

  5. Abnormal biological parameters (NFS and liver)

    proportion of patients with abnormal laboratory values (NFS and liver function) during

    Time frame: through study completion, an average of 1 year

Other outcomes

  1. Maximum Concentration (Cmax) for stiripentol, carbamazepines and its metabolites

    Cmax calculation

    Time frame: through study completion, an average of 1 year

  2. Area under the plasma concentration versus time curve (AUC) 0-8 for stiripentol, carbamazepines and its metabolites

    AUC0-8 calculation

    Time frame: through study completion, an average of 1 year

  3. Area under the plasma concentration versus time curve (AUC) 0-24 for stiripentol, carbamazepines and its metabolites

    AUC0-24 calculation

    Time frame: through study completion, an average of 1 year

  4. Time of Maximum (Tmax)concentration for stiripentol, carbamazepines and its metabolites

    Tmax calculation

    Time frame: through study completion, an average of 1 year

  5. half-life (t1/2) for stiripentol, carbamazepines and its metabolites

    t1/2 calculation

    Time frame: through study completion, an average of 1 year

  6. Pre-dose trough concentration (Ctrough) for stiripentol, carbamazepines and its metabolites

    Ctrough calculation

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Centre de Référence Epilepsies Rares / Centre Investigation Clinique (CIC) - Hôpital Necker-Enfants Malades
    Paris, 75015, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Jun 2024, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2022
First posted
Jun 15, 2022
StartActual
Oct 13, 2022
Primary completionActual
Jun 13, 2024
CompletionActual
Jun 13, 2024
Last update
Jul 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05419180
Lead sponsor
Biocodex
Responsible party
Sponsor
First posted
Jun 15, 2022
Start date
Oct 13, 2022
Primary completion
Jun 13, 2024
Completion
Jun 13, 2024
Last update
Jul 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stiripentol

Start the discussion